Grab Holdings Ltd. vs Liquidia Corporation Common Stock — how do they compare? Grab Holdings Ltd. trades at $2.9 (market cap $11.91B), while Liquidia Corporation Common Stock trades at $34.2 (market cap $3.04B). The key difference: Grab Holdings Ltd. is far larger — about 3.9× Liquidia Corporation Common Stock's market cap, and Liquidia Corporation Common Stock is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Liquidia Corporation Common Stock for 0 Days on average.
| GRAB | LQDA | |
|---|---|---|
Market Cap | $11.91B | $3.04B |
Volume | 62,622,940 | 21,111,778 |
Sector | Technology | Health |
52-Week High | $6.12 | $91.03 |
52-Week Low | $2.80 | $22.02 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $7.64B | $2.94B |
Signals from Pluang's Aura AI — not financial advice
Grab Holdings trades at $2.98, down 5.4% amid bearish technical signals, though fundamentals show strong improvement with revenue growth to $3.37B in 2025 and a shift to profitability (net income $268M). Recent news highlights a $1.49B acquisition of Atome Financial and insider buying, contrasting with mixed market sentiment.
Outlook is cautiously optimistic: analyst consensus is 91.7% buy ratings, but risks include integration of acquisitions and regional competition. The stock's current price near recent lows may offer entry points for growth-focused investors, pending Q3 2026 earnings results.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →